Compare Lamb Weston Holdings Inc (LW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs TG Therapeutics Inc — how do they compare? Lamb Weston Holdings Inc trades at $52.79 (market cap $7.23B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Lamb Weston Holdings Inc and TG Therapeutics Inc are close in size by market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| LW | TGTX | |
|---|---|---|
Market Cap | $7.23B | $7.64B |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $59.06 |
52-Week Low | $38.48 | $26.94 |
Enterprise Value | $11.10B | $7.84B |
Dividend Yield | 2.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $53.10, up 2.49% with a bullish technical signal. The stock shows strong earnings momentum with four consecutive quarterly beats, including Q2 2026 EPS of $0.87 versus $0.62 expected. Valuation metrics include a P/E of 25.28 and P/S of 1.11. Recent news highlights institutional buying and upcoming management participation in investor events, while fundamentals show $6.45B revenue with 4.39% net margin.
LW presents a mixed outlook with solid operational performance offset by margin pressure. The consensus price target of $53.86 offers limited upside, while analyst sentiment leans neutral (63% Hold). Key risks include international headwinds and cost inflation, but North American volume growth and dividend yield of 3.1% provide support. The stock trades near fair value with balanced risk-reward.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
